Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

In vitro activity of MC-352, a new 16-membered macrolide.

N X Chin1, H C Neu

  • 1Department of Medicine, College of Physicians & Surgeons, Columbia University, New York, New York 10032.

Antimicrobial Agents and Chemotherapy
|August 1, 1992
PubMed
Summary

MC-352, a novel macrolide antibiotic, demonstrates potent in vitro activity against various Gram-positive and Gram-negative bacteria, including resistant strains. Its efficacy against key pathogens like Staphylococcus aureus and Streptococcus pneumoniae suggests potential as a valuable therapeutic agent.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Postantibiotic effect of ceftibuten on respiratory pathogens.

The Pediatric infectious disease journal·1995
Same author

Ceftibuten: minimal inhibitory concentrations, postantibiotic effect and beta-lactamase stability--a rationale for dosing programs.

The Pediatric infectious disease journal·1995
Same author

In vitro activity of SCE-2787, a new cephalosporin with potent activity against Pseudomonas aeruginosa and members of the family Enterobacteriaceae.

Antimicrobial agents and chemotherapy·1994
Same author

Emerging trends in antimicrobial resistance in surgical infections. A review.

The European journal of surgery. Supplement. : = Acta chirurgica. Supplement·1994
Same author

Synergy and antagonism of fluoroquinolones with other classes of antimicrobial agents.

Drugs·1993
Same author

Gemfibrozil enhances the listeriacidal effects of fluoroquinolone antibiotics in J774 macrophages.

The Journal of experimental medicine·1992

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Pharmacology

Background:

  • Macrolide antibiotics are crucial for treating bacterial infections.
  • Emerging antibiotic resistance necessitates the development of new antimicrobial agents.
  • MC-352 is a novel macrolide with a unique chemical structure.

Purpose of the Study:

  • To evaluate the in vitro antibacterial activity of MC-352.
  • To compare MC-352's efficacy against erythromycin, clarithromycin, and rokitamycin.
  • To assess MC-352's activity against a broad spectrum of clinically relevant bacteria, including resistant isolates.

Main Methods:

  • Broth microdilution method was used to determine Minimum Inhibitory Concentrations (MICs).
  • MIC90 (concentration inhibiting 90% of isolates) and MIC50 (concentration inhibiting 50% of isolates) were determined.

Related Experiment Videos

  • Activity was tested against Gram-positive cocci (Staphylococcus, Streptococcus, Enterococcus), Gram-negative bacteria (Legionella, Bacteroides, Haemophilus, Moraxella, Enterobacteriaceae), and resistant strains.

    • Main Results:

    • MC-352 showed potent activity against erythromycin-susceptible Staphylococcus aureus and S. epidermidis (MIC90 ≤ 1 µg/ml).
    • Against erythromycin-resistant S. aureus, MC-352 exhibited significant activity (MIC50 = 2 µg/ml), comparable to rokitamycin.
    • MC-352 demonstrated superior or comparable activity against Streptococcus pyogenes, S. pneumoniae, and other streptococci compared to reference macrolides.
    • The novel macrolide was highly active against Legionella pneumophila and Moraxella spp. (MIC90 ≤ 0.25 µg/ml).
    • MC-352 displayed the most potent activity against Bacteroides fragilis (MIC90 = 8 µg/ml) and Haemophilus influenzae (MIC90 = 4 µg/ml) among tested agents.
    • Activity against Enterococcus faecalis was observed, though resistant isolates showed reduced susceptibility.
    • MC-352 was bactericidal against S. pyogenes and S. pneumoniae, with activity unaffected by human serum.
    • Limited activity was noted against Enterobacteriaceae (MIC90 ≥ 32 µg/ml).

    Conclusions:

    • MC-352 possesses broad-spectrum in vitro activity against a range of Gram-positive and Gram-negative bacteria.
    • Its potent activity against resistant strains, including erythromycin-resistant S. aureus, highlights its potential therapeutic value.
    • MC-352 demonstrates promising efficacy against key respiratory pathogens and anaerobes.
    • Further investigation into MC-352's clinical efficacy and safety profile is warranted.